Baclofen prevented the changes in c-Fos and brain-derived neutrophic factor expressions during mecamylamine-precipitated nicotine withdrawal in mice

Synapse

Volumn 68, Issue 11, 2014, Pages 508-517

  Varani, Andrés P ^a   Moutinho Machado, Lirane ^a   Balerio, Graciela N ^a,b  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Abstinence; GABAB receptors; GABAergic system; Immediate early gene expression; Neurotrophic factors

Indexed keywords

BACLOFEN; BRAIN DERIVED NEUROTROPHIC FACTOR; MECAMYLAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PROTEIN C FOS;

ANIMAL; ANTIBODY SPECIFICITY; BASAL GANGLION; DRUG EFFECTS; GENETICS; HIPPOCAMPUS; MALE; METABOLISM; MOUSE; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALS; BACLOFEN; BASAL GANGLIA; BRAIN-DERIVED NEUROTROPHIC FACTOR; HIPPOCAMPUS; MALE; MECAMYLAMINE; MICE; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS C-FOS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84908454435     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21763     Document Type: Article

References (63)

1. Alzoubi KH, Alkadhi KA. 2014. Chronic nicotine treatment reverses hypothyroidism-induced impairment of L-LTP induction phase: Critical role of CREB. Mol Neurobiol 49:1245-1255.
2. Baldwin PR, Alanis R, Salas R. 2011. The role of the Habenula in nicotine addiction. J Addict Res Ther 20:S1.
3. Balerio GN, Rubio MC. 2002. Baclofen analgesia: Involvement of the GABAergic system. Pharmacol Res 46:281-286.
4. Balerio GN, Aso E, Berrendero F, Murtra P, Maldonado R. 2004. Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 10:2737-2748.
5. Balfour DJK. 2009. The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol 192:209-233.
6. Bester H, De Felipe C, Hunt SP. 2001. The NK1 receptor is essential for the full expression of noxious inhibitory controls in the mouse. J Neurosci 21:1039-1046.
7. Bruijnzeel AW, Ford J, Rogers JA, Scheick S, Ji Y, Bishnoi M, Alexander JC. 2012. Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats. Pharmacol Biochem Behav 101:62-68.
8. Carboni E, Bortone L, Giua C, Di Chiara G. 2000. Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend 58:93-102.
9. Castrén E, da Penha Berzaghi M, Lindholm D, Thoenen H. 1993. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp Neurol 122:244-252.
10. Chao J, Nestler EJ. 2004. Molecular neurobiology of drug addiction. Annu Rev Med 55:113-132.
11. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. 1997. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: Evidence for anterograde axonal transport. J Neurosci 7:2295-2313.
12. Damaj MI, Siu EC, Sellers EM, Tyndale RF, Martin BR. 2007. Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 320:250-257.
13. De Biasi M, Dani JA. 2011. Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci 34:105-130.
14. De Biasi M, Salas R. 2008. Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp Biol Med (Maywood) 233:917-929.
15. Delfino MA, Stefano AV, Ferrario JE, Taravini IR, Murer MG, Gershanik OS. 2004. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav Brain Res 152:297-306.
16. Diaz SL, Kemmling AK, Rubio MC, Balerio GN. 2001. Lack of sex-related differences in the prevention by baclofen of the morphine withdrawal syndrome in mice. Behav Pharmacol 12:75-79.
17. Diaz SL, Kemmling AK, Balerio GN. 2003. Baclofen reestablishes striatal and cortical dopamine concentrations during naloxone-precipitated withdrawal. Neurochem Int 42:293-298.
18. Diaz SL, Kemmling AK, Bonavita CD, Rubio MC, Balerio GN. 2004. Baclofen reestablishes micro-opioid receptor levels modified by morphine withdrawal syndrome in either sex. Synapse 54:24-29.
19. Diaz SL, Barros VG, Antonelli MC, Rubio MC, Balerio GN. 2006. Morphine withdrawal syndrome and its prevention with baclofen: Autoradiographic study of mu-opioid receptors in prepubertal male and female mice. Synapse 60:132-140.
20. Dragunow M, Faull R. 1989. The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 29:261-265.
21. Ernfors P, Wetmore C, Olson L, Persson H. 1990. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. Neuron 5:511-526.
22. Frenois F, Cador M, Caillé S, Stinus L, Le Moine C. 2002. Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 7:1377-1389.
23. Fung YK, Schimid MJ, Anderson TM, Lau Y. 1996. Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol Biochem Behav 53:635-640.
24. Gäddnäs H, Pietilä K, Ahtee L. 2000. Effects of chronic oral nicotine treatment and its withdrawal on locomotor activity and brain monoamines in mice. Behav Brain Res 113:65-72.
25. Gäddnäs H, Piepponen TP, Ahtee L. 2002. Mecamylamine decreases accumbal dopamine output in mice treated chronically with nicotine. Neurosci Lett 330:219-222.
26. Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L. 2010. Role of BDNF and GDNF in drug reward and relapse: A review. Neurosci Biobehav Rev 35:157-171.
27. Ghosh A, Carnahan J, Greenberg ME. 1994. Requirement for BDNF in activity-dependent survival of cortical neurons. Science 263:1618-1623.
28. Graybiel AM, Moratalla R, Robertson HA. 1990. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 87:6912-6916.
29. Guide for the Care and Use of Laboratory Animals. 1985. National Research Council(US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 8th ed. Washington, DC: National Academies Press (US).
30. Hildebrand BE, Nomikos GG, Hertel P, Schilström B, Svensson TH. 1998. Reduce dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779:214-225.
31. Kivinummi T, Kaste K, Rantamäki T, Castrén E, Ahtee L. 2011. Alterations in BDNF and phospho-CREB levels following chronic oral nicotine treatment and its withdrawal in dopaminergic brain areas of mice. Neurosci Lett 491:108-112.
32. Klemm WR. 2004. Habenular and interpeduncularis nuclei: Shared components in multiple-function networks. Med Sci Monit 10: RA261-273.
33. Lipsky RH, Marini AM. 2007. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 1122:130-143.
34. Marcinkiewcz CA, Prado MM, Isaac SK, Marshall A, Rylkova D, Bruijnzeel AW. 2009. Corticotropin-releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats. Neuropsychopharmacology 34:1743-1752.
35. Markou A. 2008. Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 363:3159-3168.
36. Marttila K, Raattamaa H, Ahtee L. 2006. Effects of chronic nicotine administration and its withdrawal on striatal FosB/DeltaFosB and c-Fos expression in rats and mice. Neuropharmacology 51:44-51.
37. McAllister AK. 1999. Subplate neurons: A missing link among neurotrophins, activity, and ocular dominance plasticity? Proc Natl Acad Sci USA 24:13600-13602.
38. Morgan JI, Curran T. 1991. Stimulus-transcription coupling in the nervous system: Involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14:421-451.
39. Ortega LA1, Tracy BA, Gould TJ, Parikh V. 2013. Effects of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J mice. Behav Brain Res 238:134-145.
40. Pagliusi SR, Tessari M, DeVevey S, Chiamulera C, Pich EM. 1996. The reinforcing properties of nicotine are associated with a specific patterning of c-fos expression in the rat brain. Eur J Neurosci 11:2247-2256.
41. Panagis G, Hildebrand BE, Svensson TH, Nomikos GG. 2000. Selective c-fos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Synapse 35:15-25.
42. Pattwell SS, Bath KG, Perez-Castro R, Lee FS, Chao MV, Ninan I. 2012. The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex. J Neurosci 7:2410-2421.
43. Paxinos G, Franklin K. 2004. The mouse brain in stereotaxic coordinates, 2nd ed. London: Academic Press.
44. Pedrón VT, Taravini IR, Induni AS, Balerio GN. 2013. Baclofen did not modify sexually dimorphic c-Fos expression during morphine withdrawal syndrome. Synapse 67:118-126.
45. Plaza-Zabala A, Flores Á, Maldonado R, Berrendero F. 2012. Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal. Biol Psychiatry 71:214-223.
46. Rada P, Jensen K, Hoebel BG. 2001. Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. Psychopharmacology 157:105-110.
47. Rahman S, Zhang J, Engleman EA, Corrigall WA. 2004. Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: A microdialysis study. Neuroscience 129:415-424.
48. Salas R, Pieri F, De Biasi M. 2004. Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. J Neurosci 24:10035-10039.
49. Salas R, Sturm R, Boulter J, De Biasi M. 2009. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J Neurosci 29:3014-3018.
50. Salminen O, Seppä T, Gäddnäs H, Ahtee L. 1999. The effects of acute nicotine on the metabolism of dopamine and the expression of Fos protein in striatal and limbic brain areas of rats during chronic nicotine infusion and its withdrawal. J Neurosci 19:8145-8151.
51. Salminen O, Seppä T, Gäddnäs H, Ahtee L. 2000. Effect of acute nicotine on Fos protein expression in rat brain during chronic nicotine and its withdrawal. Pharmacol Biochem Behav 66:87-93.
52. Schilström B, De Villiers S, Malmerfelt A, Svensson TH, Nomikos GG. 2000. Nicotine-induced Fos expression in the nucleus accumbens and the medial prefrontal cortex of the rat: Role of nicotinic and NMDA receptors in the ventral tegmental area. Synapse 36:314-321.
53. Schroeder BE, Binzak JM, Kelley AE. 2001. A common profile of prefrontal cortical activation following exposure to nicotine- or chocolate-associated contextual cues. Neuroscience 105:535-545.
54. SENASA. (Resolución 617/2002): Requisitos, condiciones y procedimientos para la habilitación técnica de laboratorios que posean bioterios de producción, mantenimiento y local de experimentación.
55. Slotkin TA, Seidler FJ. 2007. A unique role for striatal serotonergic systems in the withdrawal from adolescent nicotine administration. Neurotoxicol Teratol 29:10-16.
56. Slotkin TA, Ryde IT, Seidler FJ. 2007. Separate or sequential exposure to nicotine prenatally and in adulthood: Persistent effects on acetylcholine systems in rat brain regions. Brain Res Bull 74:91-103.
57. Turner JR, Castellano LM, Blendy JA. 2011. Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine Tob Res 13:41-46.
58. (B) receptors involvement in the effects induced by nicotine on anxiety-related behaviour in mice. Pharmacol Res 65:507-513.
59. Varani AP, Moutinho LM, Calvo M, Balerio GN. 2011. Ability of baclofen to prevent somatic manifestations and neurochemical changes during nicotine withdrawal. Drug Alcohol Depend 119:e5-12.
60. (B1) knockout mice. Neuropharmacology 63:863-872.
61. Varani AP, Antonelli MC, Balerio GN. 2013. Mecamylamine-precipitated nicotine withdrawal syndrome and its prevention with baclofen: An autoradiographic study of α4β2 nicotinic acetylcholine receptors in mice. Prog Neuropsychopharmacol Biol Psychiatry 44:217-225.
62. Varani AP, Aso E, Moutinho Machado L, Maldonado R, Balerio GN. 2014. Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. Psychopharmacology 231:3031-3040.
63. Xu B, Gottschalk W, Chow A, Wilson RI, Schnell E, Zang K, Wang D, Nicoll RA, Lu B, Reichardt LF. 2000. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: Modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci 18:6888-6897.